LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Aandelen Lijst・Design Therapeutics Inc

Design Therapeutics Inc

Gesloten

10.49 -2.15

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.32

Max

10.68

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.6M -18M
EPS	-0.29
Werknemers	54
EBITDA	-1.5M -20M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+82.5% upside

Dividenden
By Dow Jones
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-115M 685M
Vorige openingsprijs	12.64
Vorige sluitingsprijs	10.49

Design Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 mei 2026, 23:08 UTC

Acquisities, Fusies, Overnames

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 mei 2026, 23:06 UTC

Acquisities, Fusies, Overnames

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 mei 2026, 20:53 UTC

Winsten

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 mei 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

29 mei 2026, 20:33 UTC

Marktinformatie

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 mei 2026, 20:11 UTC

Winsten

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mei 2026, 19:47 UTC

Winsten

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 mei 2026, 19:36 UTC

Marktinformatie

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 mei 2026, 19:34 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

29 mei 2026, 19:34 UTC

Marktinformatie

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 mei 2026, 19:22 UTC

Marktinformatie

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 mei 2026, 19:05 UTC

Acquisities, Fusies, Overnames

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 mei 2026, 18:19 UTC

Marktinformatie

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 mei 2026, 18:12 UTC

Acquisities, Fusies, Overnames

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 mei 2026, 18:11 UTC

Marktinformatie

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 mei 2026, 18:10 UTC

Marktinformatie

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 mei 2026, 17:55 UTC

Winsten

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mei 2026, 17:55 UTC

Marktinformatie

NEAR Protocol Nearly Doubles in May -- Market Talk

29 mei 2026, 17:38 UTC

Marktinformatie

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 mei 2026, 17:00 UTC

Winsten

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

29 mei 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

29 mei 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

29 mei 2026, 16:02 UTC

Marktinformatie

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 mei 2026, 15:55 UTC

Marktinformatie

Global Equities Roundup: Market Talk

29 mei 2026, 15:55 UTC

Marktinformatie

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 mei 2026, 15:50 UTC

Acquisities, Fusies, Overnames

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 mei 2026, 15:50 UTC

Acquisities, Fusies, Overnames

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 mei 2026, 15:40 UTC

Marktinformatie

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 mei 2026, 15:20 UTC

Marktinformatie

Canada's Economy Not Looking All That Bright -- Market Talk

Peer Vergelijking

Prijswijziging

Design Therapeutics Inc Prognose

Koersdoel

By TipRanks

82.5% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 19.6 USD 82.5%

Hoogste 22 USD

Laagste 15 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Design Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Design Therapeutics Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.